ADMA Biologics (ADMA) concentration risks

The company's single disclosed concentration is customer-driven: historically, a few customers have accounted for a significant amount of total revenue and accounts receivable. By disclosed size this is a moderate exposure — neither the tightest single-name dependency in the sector nor a broadly diversified book — and its character is one of dependency rather than structural breadth, reflecting reliance on a small set of buyers for a meaningful share of the revenue base. Because the filing names no individual customer, geography, or specific share figure, the exposure is diffuse in its specifics but the filing nonetheless flags it as a recurring pattern. The combination of revenue concentration and accounts receivable concentration is worth noting: a stumble at a key account could move both the top line and the balance sheet simultaneously. The absence of a named counterparty or a specific percentage does, however, limit precision in sizing the exposure independently. There is no separately disclosed product, geographic, or supplier concentration layered on top of this customer dependency in the disclosed claims. On balance, the profile is straightforward: a moderate customer concentration without a named single-account cliff, calling for standard tracking of customer diversification trends and any disclosure of customer-level shifts rather than heightened single-name monitoring.

For the engine’s reasoning on ADMA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.